TITLE PAGE

Type of Article: Research Article

**Aaaa

ABSTRACT

Background:
Aaaa

INTRODUCTION

Aaaa

aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa.Aaaaaaaaaaaaaaaaaaaa

DECLARATIONS

Funding: Aaaaaaaaaaaaaaaaaaaaa

Conflict of interest: Aaaaaaaaaaaaaaaaaaaaa

Ethical approval: Aaaaaaaaaaaaaaaaaaaaa

REFERENCES

1. Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2006;8(2):156-63.
2. O'Brien C. Drug addiction and drug abuse. In: Brunton LB, Lazo JS, Parker KL, eds.Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2005:607-29.
3. National Cancer Institute. Fact sheet: targeted cancer therapies, 2012. Available at http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted#q1. Accessed 9 June 2014.

General guidelines on references

References should be numbered consecutively as they appear in the text. Reference citations in the text should be identified by numbers in superscript after the punctuation marks. All authors should be quoted for papers with up to six authors; for papers with more than six authors, the first six should be quoted followed by et al.

Journal article:

Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2006;8(2):156-63.

Book chapter:

O'Brien C. Drug addiction and drug abuse. In: Brunton LB, Lazo JS, Parker KL, eds.Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2005: 607-629.

Website:

National Cancer Institute. Fact sheet: targeted cancer therapies, 2012. Available at http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted#q1. Accessed 9 June 2014.

Table 1: Aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa.

Table 2: Aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa.

Figure 1: Aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa.

Figure 2: Aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa.